The HST maker will immediately begin commercialization of the device, leveraging its dedicated US salesforce.
Key takeaways:
- Somfit D (single-use) is FDA-cleared, increasing the addressable US market for Somfit.
- Complements the reusable Somfit, creating an EEG-based platform serving both high-volume single-use and multi-night reusable diagnostic markets
- US salesforce in place, providers already engaged, and commercial rollout commencing immediately.
- Somfit D is now cleared in Australia, New Zealand, and the EU.
The Food & Drug Administration (FDA) has granted 510(k) clearance for Compumedics Ltd’s Somfit D device, a disposable version of the company’s EEG-based Somfit home sleep test (HST).
The HST addresses the US market’s demand for single-use (disposable) solutions, a market that already includes WatchPAT ONE and NightOwl. In combination with the reusable Somfit, Compumedics now delivers an EEG-based platform that spans both single-use and reusable markets. Compumedics will rely on this dual-platform strategy to create a defensible competitive advantage, expand its addressable market, and position the company to capture market share across the entire spectrum of home sleep testing.
With Somfit D now FDA-cleared, Compumedics will immediately begin commercialization, leveraging a dedicated US salesforce already in place, established relationships with independent diagnostic testing facilities and sleep centers that prioritize single-use workflows, and a recurring revenue engine spanning software-as-a-service subscriptions (SaaS), consumables, and device sales.
“The FDA clearance of Somfit D is a transformational milestone for Compumedics,” says David Burton, PhD, executive chairman and CEO, in a release. “With a single-use device engineered for scale, we are entering the US sleep diagnostics market with a disruptive solution that directly addresses provider needs. Together with the reusable Somfit, we are positioned to capture meaningful share of a market worth up to US$240M annually and to accelerate our recurring revenue growth for years to come.”
The Somfit platform is designed to disrupt traditional sleep diagnostics by offering scalable SaaS economics with high-margin recurring revenue, clinical-grade data in the home with EEG signals equivalent to in-lab studies, convenience for patients by reducing reliance on hospital-based testing, and lower costs for providers by streamlining operations and improving capacity.
Somfit D has now been cleared in Australia, New Zealand, the European Union, and the United States, providing Compumedics with global reach and multiple incremental revenue streams. Compumedics anticipates progressive revenue contribution from Somfit D beginning in FY26 as adoption accelerates across the United States.
Cool product